Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05723198




Registration number
NCT05723198
Ethics application status
Date submitted
3/02/2023
Date registered
10/02/2023
Date last updated
26/09/2024

Titles & IDs
Public title
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Scientific title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Secondary ID [1] 0 0
I4V-MC-JAIO
Secondary ID [2] 0 0
16875
Universal Trial Number (UTN)
Trial acronym
BRAVE-AA-PEDS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Areata Alopecia 0 0
Alopecia 0 0
Hypotrichosis 0 0
Hair Diseases 0 0
Skin Diseases 0 0
Pathological Conditions, Anatomical 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Skin 0 0 0 0
Other skin conditions
Skin 0 0 0 0
Dermatological conditions
Public Health 0 0 0 0
Epidemiology

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Baricitinib
Treatment: Drugs - Placebo

Experimental: Baricitinib High Dose - Participants will receive baricitinib high dose orally.

Experimental: Baricitinib Low Dose - Participants will receive baricitinib low dose orally.

Placebo comparator: Placebo - Participants will receive placebo


Treatment: Drugs: Baricitinib
Administered orally

Treatment: Drugs: Placebo
Administered orally
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) =20
Timepoint [1] 0 0
Week 36
Secondary outcome [1] 0 0
Percent Change from Baseline in SALT Score
Timepoint [1] 0 0
Baseline, Week 36
Secondary outcome [2] 0 0
Percentage of Participants Achieving At Least 90% Improvement from Baseline (SALT90)
Timepoint [2] 0 0
Week 36
Secondary outcome [3] 0 0
Percentage of Participants Achieving an Absolute SALT =10
Timepoint [3] 0 0
Week 36
Secondary outcome [4] 0 0
Percentage of Participants with Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 Among Participants 12 Years and Older with PRO for Scalp Hair Assessment Score =3 at Baseline
Timepoint [4] 0 0
Week 36
Secondary outcome [5] 0 0
Mean Change from Baseline in SALT Score
Timepoint [5] 0 0
Baseline, Week 36
Secondary outcome [6] 0 0
Percentage of Participants Achieving At Least 50% Improvement from Baseline (SALT50)
Timepoint [6] 0 0
Week 36
Secondary outcome [7] 0 0
Percentage of Participants Achieving At Least 75% Improvement from Baseline (SALT75)
Timepoint [7] 0 0
Week 36
Secondary outcome [8] 0 0
Percentage of Participants Achieving At Least 100% Improvement from Baseline (SALT100)
Timepoint [8] 0 0
Week 36
Secondary outcome [9] 0 0
Percentage of Participants Achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 Among Participants with CLinRO Measure for EB Hair Loss =2 at Baseline
Timepoint [9] 0 0
Week 36
Secondary outcome [10] 0 0
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 Among Participants with CLinRO Measure for EL Hair Loss =2 at Baseline
Timepoint [10] 0 0
Week 36
Secondary outcome [11] 0 0
Percentage of Participants Achieving PRO Measure for EB 0 or 1 (Among Participants 12 Years or Older with PRO Measure for EB =2 at Baseline)
Timepoint [11] 0 0
Week 36
Secondary outcome [12] 0 0
Percentage of Participants Achieving PRO Measure for EL 0 or 1 (Among Participants 12 Years or Older with PRO Measure for EL =2 at Baseline)
Timepoint [12] 0 0
Week 36
Secondary outcome [13] 0 0
Mean Change from Baseline in Hospital Anxiety Depression Scale (HADS)
Timepoint [13] 0 0
Week 36
Secondary outcome [14] 0 0
Mean Change from Baseline in Patient-Reported Outcome Measurement Information System (PROMIS) Anxiety Score
Timepoint [14] 0 0
Baseline, Week 36
Secondary outcome [15] 0 0
Mean Change from Baseline in PROMIS Depression Score
Timepoint [15] 0 0
Baseline, Week 36
Secondary outcome [16] 0 0
Mean Change from Baseline in PROMIS Peer Relationship Score
Timepoint [16] 0 0
Baseline, Week 36
Secondary outcome [17] 0 0
Mean Change from Baseline in Family Dermatology Life Quality Index (FDLQI)
Timepoint [17] 0 0
Baseline, Week 36
Secondary outcome [18] 0 0
Pharmacokinetics (PK): Maximum Concentration (Cmax)
Timepoint [18] 0 0
Baseline through Week 36
Secondary outcome [19] 0 0
PK: Area Under the Concentration Curve (AUC)
Timepoint [19] 0 0
Baseline through Week 36
Secondary outcome [20] 0 0
Change of Immunoglobulin G (IgG) Titers
Timepoint [20] 0 0
Pre-Vaccination to 4 Weeks and 12 Weeks Post-Vaccination

Eligibility
Key inclusion criteria
* Enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old).
* Have severe areata alopecia (AA) for at least 1 year
* Diagnosis for at least 1 year
* Current AA episode of at least 6 months' duration
* SALT score =50% at screening and baseline
* History of trial and failure with at least 1 available treatment (topical or other) for AA
* History of psychological counseling related to AA
* Current episode of severe AA of less than 8 years.

* Note: Participants who have severe AA for =8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.
Minimum age
6 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Primarily "diffuse" type of AA (characterized by diffuse hair shedding).
* Are currently experiencing other forms of alopecia including, but not limited to trichotillomania, telogen effluvium, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that would interfere with evaluations of the effect of study medication on AA.
* Are largely or wholly incapacitated permitting little or no self-care, such as being bedridden
* Have uncontrolled arterial hypertension
* Have had major surgery within 8 weeks prior to screening or will require major surgery during the study
* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking IP or interfere with the interpretation of data.
* Have a positive test for hepatitis B virus (HBV) infection
* Have hepatitis C virus (HCV) infection (positive for anti hepatitis C antibody with confirmed presence of HCV ribonucleic acid [RNA]).
* Have evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/02/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/08/2029
Actual
Sample size
Target
595
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Skin and Cancer Foundation Australia - Darlinghurst Clinic - Darlinghurst
Recruitment hospital [2] 0 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [3] 0 0
Veracity Clinical Research Pty Ltd - Woolloongabba
Recruitment hospital [4] 0 0
Sinclair Dermatology - Melbourne
Recruitment hospital [5] 0 0
Institute for Skin, Health, and Immunity - Mitcham
Recruitment postcode(s) [1] 0 0
02010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
3002 - Melbourne
Recruitment postcode(s) [5] 0 0
3132 - Mitcham
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Utah
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Wisconsin
Country [26] 0 0
Argentina
State/province [26] 0 0
Buenos Aires
Country [27] 0 0
Argentina
State/province [27] 0 0
Buenos Air
Country [28] 0 0
Argentina
State/province [28] 0 0
Provincia De Tucuman
Country [29] 0 0
Argentina
State/province [29] 0 0
Tucumán
Country [30] 0 0
Canada
State/province [30] 0 0
Alberta
Country [31] 0 0
Canada
State/province [31] 0 0
British Columbia
Country [32] 0 0
Canada
State/province [32] 0 0
Manitoba
Country [33] 0 0
Canada
State/province [33] 0 0
Ontario
Country [34] 0 0
France
State/province [34] 0 0
Brest CEDEX 2
Country [35] 0 0
France
State/province [35] 0 0
Marseille
Country [36] 0 0
France
State/province [36] 0 0
Nantes
Country [37] 0 0
France
State/province [37] 0 0
Nice
Country [38] 0 0
France
State/province [38] 0 0
Paris
Country [39] 0 0
France
State/province [39] 0 0
Tours Cedex
Country [40] 0 0
Germany
State/province [40] 0 0
Bayern
Country [41] 0 0
Germany
State/province [41] 0 0
Niedersachsen
Country [42] 0 0
Germany
State/province [42] 0 0
Schleswig-Holstein
Country [43] 0 0
Germany
State/province [43] 0 0
Berlin
Country [44] 0 0
Germany
State/province [44] 0 0
Dresden
Country [45] 0 0
Germany
State/province [45] 0 0
Frankfurt am Main
Country [46] 0 0
Germany
State/province [46] 0 0
Halle
Country [47] 0 0
Germany
State/province [47] 0 0
Hamburg
Country [48] 0 0
Germany
State/province [48] 0 0
Mainz
Country [49] 0 0
Germany
State/province [49] 0 0
Muenster
Country [50] 0 0
Hungary
State/province [50] 0 0
Csongrad
Country [51] 0 0
Hungary
State/province [51] 0 0
Hajdu-Bihar
Country [52] 0 0
Hungary
State/province [52] 0 0
Budapest
Country [53] 0 0
Hungary
State/province [53] 0 0
Pecs
Country [54] 0 0
Japan
State/province [54] 0 0
Fukuoka
Country [55] 0 0
Japan
State/province [55] 0 0
Miyagi
Country [56] 0 0
Japan
State/province [56] 0 0
Shizuoka
Country [57] 0 0
Japan
State/province [57] 0 0
Tokyo
Country [58] 0 0
Japan
State/province [58] 0 0
Yamaguchi
Country [59] 0 0
Japan
State/province [59] 0 0
Niigata
Country [60] 0 0
Japan
State/province [60] 0 0
Osaka
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Chungcheongnam-do [Chungnam]
Country [62] 0 0
Korea, Republic of
State/province [62] 0 0
Geonggi-do
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Gyeonggi-do
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Incheon-gwangyeoksi [Incheon]
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Jung-gu
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Pusan-Kwangyokshi
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Seoul, Korea
Country [68] 0 0
Korea, Republic of
State/province [68] 0 0
Seoul-teukbyeolsi [Seoul]
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Taegu-Kwangyokshi
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Jeonju-si
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Seoul
Country [72] 0 0
Mexico
State/province [72] 0 0
Jalisco
Country [73] 0 0
Mexico
State/province [73] 0 0
Nuevo León
Country [74] 0 0
Mexico
State/province [74] 0 0
Chihuahua
Country [75] 0 0
Mexico
State/province [75] 0 0
Mexico City
Country [76] 0 0
Mexico
State/province [76] 0 0
Veracruz
Country [77] 0 0
Poland
State/province [77] 0 0
Lodzkie
Country [78] 0 0
Poland
State/province [78] 0 0
Malopolskie
Country [79] 0 0
Poland
State/province [79] 0 0
Masovian
Country [80] 0 0
Poland
State/province [80] 0 0
Podkarpackie
Country [81] 0 0
Poland
State/province [81] 0 0
Pomorskie
Country [82] 0 0
Poland
State/province [82] 0 0
Bialystok
Country [83] 0 0
Poland
State/province [83] 0 0
Bydgoszcz
Country [84] 0 0
Poland
State/province [84] 0 0
Katowice
Country [85] 0 0
Poland
State/province [85] 0 0
Kielce
Country [86] 0 0
Poland
State/province [86] 0 0
Ostrowiec Swietokrzyski
Country [87] 0 0
Poland
State/province [87] 0 0
Szczecin
Country [88] 0 0
Poland
State/province [88] 0 0
Warszawa
Country [89] 0 0
Poland
State/province [89] 0 0
Wroclaw
Country [90] 0 0
Poland
State/province [90] 0 0
Slaskie
Country [91] 0 0
Spain
State/province [91] 0 0
Catalunya [Cataluña]
Country [92] 0 0
Spain
State/province [92] 0 0
Alicante
Country [93] 0 0
Spain
State/province [93] 0 0
Badalona
Country [94] 0 0
Spain
State/province [94] 0 0
Bilbao
Country [95] 0 0
Spain
State/province [95] 0 0
Madrid
Country [96] 0 0
Spain
State/province [96] 0 0
Pamplona
Country [97] 0 0
Spain
State/province [97] 0 0
Pozuelo de Alarcon
Country [98] 0 0
Spain
State/province [98] 0 0
Valencia
Country [99] 0 0
Taiwan
State/province [99] 0 0
New Taipei
Country [100] 0 0
Taiwan
State/province [100] 0 0
Taichung
Country [101] 0 0
Taiwan
State/province [101] 0 0
Tainan
Country [102] 0 0
Taiwan
State/province [102] 0 0
Taipei
Country [103] 0 0
Taiwan
State/province [103] 0 0
Taoyuan

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.

The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Trial website
https://clinicaltrials.gov/study/NCT05723198
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Address 0 0
Country 0 0
Phone 0 0
-317-615-4559
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05723198